Skip to content
Companies

Syncromune

Cryoablation-based immunotherapy for prostate cancer

Raised to date

$144.8M

of $144.8M offered across 1 Form D filing

Investors
77
Last filed
May 11, 2026

About

Syncromune is a clinical-stage biopharmaceutical company in Fort Lauderdale, Florida developing in situ immunotherapies for incurable metastatic solid tumors. Its SYNC-T platform combines tumor cryoablation with an intratumoral multi-target biologic drug so that patient-specific tumor antigens, immunomodulatory biologics and immune cells are synchronized in tumor-draining lymph nodes to activate an anti-tumor T cell response. The lead program, SYNC-T Therapy SV-102, targets metastatic castration-resistant prostate cancer and is in the LEGION-100 Phase 2 trial after Phase 1 data reported an 87% overall response rate and 53% complete response rate. The company was founded in 2020 and has raised roughly $130M, including a $100M Series A.

An entirely in situ approach: the patient's own tumor is frozen in place to release antigens and then dosed with a combination biologic, so the tumor itself acts as the vaccine rather than requiring an ex vivo manufactured cell or neoantigen product.

Funding

  • EquityFiled May 11, 2026Form D/A
    $144.8M/ $144.8M

Product

SYNC-T Therapy SV-102

Clinical-stage oncology therapeutic

An investigational in situ combination immunotherapy for metastatic castration-resistant prostate cancer that pairs tumor cryoablation with an intratumoral multi-target biologic, currently in the LEGION-100 Phase 2 clinical trial.

  • Cryoablation of the tumor to release patient-specific tumor antigens in situ
  • Intratumoral multi-target immunomodulatory biologic delivered at the same session
  • Activation of anti-tumor T cell responses in tumor-draining lymph nodes

Built for

Patients with incurable metastatic solid tumors, initially metastatic castration-resistant prostate cancer, reached through oncologists and interventional radiologists at cancer centers

People on file